
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. reported a total revenue of $44 million in its recent financial performance, reflecting a 15% year-over-year growth on a constant currency basis, indicating a slight increase from the previous quarter's 14% growth. The continuing rise in gene therapy programs, particularly in oncology and rare diseases, suggests a robust increase in demand for CryoPort's integrated temperature-controlled supply chain solutions as the market embraces these therapies. Additionally, the expectation of increased commercial revenue and clinical trial activity aligns with the overall positive market dynamics, further supporting a favorable outlook for CryoPort's stock.
Bears say
CryoPort Inc. is experiencing a slowdown in funding for start-up companies in its sector, with a decline in Series A and seed funding, which may impact future growth. The company's Life Sciences Services revenue growth has decelerated, recording a 16% increase compared to 21% in the previous quarter, and its adjusted EBITDA margin remains negative at (1.5%), below the consensus estimate. Additionally, the bear case scenario anticipates ongoing revenue challenges due to a reduced pace of cell and gene therapy approvals, coupled with a decrease in demand for MVE freezers, ultimately leading to lowered earnings per share projections for 2026.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares